Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Deferred Tax Liability: 2013-2025

Historic Non-Current Deferred Tax Liability for Lineage Cell Therapeutics (LCTX) over the last 9 years, with Sep 2025 value amounting to $273,000.

  • Lineage Cell Therapeutics' Non-Current Deferred Tax Liability changed negligibly% to $273,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $273,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $273,000 for FY2024, which is negligibly% changed negligibly from last year.
  • Lineage Cell Therapeutics' Non-Current Deferred Tax Liability amounted to $273,000 in Q3 2025, which was down 0.00% from $273,000 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Non-Current Deferred Tax Liability peaked at $2.1 million during Q1 2021, and registered a low of $273,000 during Q1 2023.
  • Its 3-year average for Non-Current Deferred Tax Liability is $273,000, with a median of $273,000 in 2025.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Non-Current Deferred Tax Liability soared by 132.21% in 2022, and later slumped by 86.85% in 2023.
  • Lineage Cell Therapeutics' Non-Current Deferred Tax Liability (Quarterly) stood at $2.1 million in 2021, then remained steady at $2.1 million in 2022, then slumped by 86.85% to $273,000 in 2023, then remained steady at $273,000 in 2024, then remained steady at $273,000 in 2025.
  • Its Non-Current Deferred Tax Liability stands at $273,000 for Q3 2025, versus $273,000 for Q2 2025 and $273,000 for Q1 2025.